Eletriptan
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Eletriptan: From Migraine to Migraine with Brainstem Aura
One-Sentence Summary
Eletriptan is a triptan (5-HT1B/1D receptor agonist) originally used for the acute treatment of migraine. The TxGNN model predicts it may be effective for migraine with brainstem aura, but there are currently 0 registered clinical trials and 17 publications (none specific to this subtype), so the prediction rests mainly on general migraine evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Migraine disorder (taken from the knowledge-graph indication records, because the Singapore registration record gives no indication text) |
| Predicted New Indication | Migraine with brainstem aura |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L4 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Eletriptan is a selective 5-HT1B/1D receptor agonist. The literature compiled for this report describes it as acting by constricting cranial blood vessels and inhibiting release of trigeminal neuropeptides. Detailed mechanism data were not available in the structured drug record, so this description comes from the published reviews.
Migraine with brainstem aura is a migraine subtype that shares the core biology of migraine: trigeminovascular activation and cortical spreading depression. A mechanistic link is therefore plausible.
However, the link does not by itself support efficacy. Triptans have historically been cautioned against, or contraindicated, in this subtype because of the theoretical risk of vasoconstriction. The retrieved literature is general migraine evidence (guidelines, reviews, pharmacology) and is not specific to brainstem aura. One randomised study (PMID 15469451) found no benefit when eletriptan was taken during the aura phase. One case report (PMID 25155004) describes a myocardial infarction after eletriptan.
Clinical Trial Evidence
Currently no related clinical trials registered for migraine with brainstem aura.
Literature Evidence
None of the publications below is specific to brainstem aura.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 15469451 | 2004 | RCT | Eur J Neurol | Eletriptan 80 mg taken during the aura phase of migraine with aura showed no benefit |
| 11844898 | 2002 | Randomised, double-blind trial | Eur Neurol | Eletriptan 40 and 80 mg compared with ergotamine plus caffeine and placebo in acute migraine |
| 12807526 | 2003 | Clinical study | Cephalalgia | Eletriptan in patients (n=446) with previous poor response or intolerance to oral sumatriptan |
| 25600718 | 2015 | Guideline / evidence review | Headache | American Headache Society evidence assessment of acute migraine drug therapies |
| 11687056 | 2001 | Review | Cochrane Database Syst Rev | Evidence-based assessment of eletriptan for acute migraine (a later version was withdrawn, PMID 17636718) |
| 12498013 | 2002 | Review | Curr Opin Investig Drugs | Eletriptan has higher affinity than sumatriptan for 5-HT1D (6-fold) and 5-HT1B (3-fold) receptors |
| 21028917 | 2010 | Review | Paediatr Drugs | Triptan use in paediatric migraine |
| 25155004 | 2014 | Case report | Rev Port Cardiol | Non-ST-elevation myocardial infarction hours after eletriptan in a patient with migraine with aura |
| 11050304 | 2000 | Laboratory study | Eur J Pharmacol | Eletriptan and sumatriptan contractile effects on human isolated meningeal and coronary arteries |
| 17501848 | 2007 | Clinical study | Headache | Eletriptan improved functional and work productivity outcomes in migraine |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN11767P | RELPAX TABLET 40 mg (Pfizer Italia S.r.l.) | Film-coated tablet (oral) | Not stated in the registration record |
Safety Considerations
- Contraindications and warnings from the knowledge graph (not label text): The following conditions are linked to eletriptan.
- Cardiovascular: hypertension, coronary artery disease, myocardial infarction, myocardial ischaemia, Prinzmetal angina, peripheral vascular disease, Raynaud disease.
- Cerebrovascular: stroke, transient ischaemic attack, cerebral infarction, brain ischaemia, vertebrobasilar insufficiency.
- Migraine subtype: familial or sporadic hemiplegic migraine.
- Other: serotonin syndrome, ischaemic bowel disease, liver disease or failure, diabetes, obesity.
- Drug interactions: 94 interactions are recorded.
- Major: clarithromycin (a strong CYP3A4 inhibitor), the serotonergic or appetite-suppressant agents lorcaserin, fenfluramine, dexfenfluramine and sibutramine, and the 5-HT3 antagonists ondansetron, granisetron, dolasetron and palonosetron.
- Moderate: aprepitant, morphine, cimetidine, clotrimazole and miconazole.
Please refer to the package insert for the full official warnings, because the label text was not available for this report.
Conclusion and Next Steps
Decision: Hold
Rationale: The high TxGNN score is not backed by any trial or subtype-specific publication. The available evidence is general migraine data, one study showing no benefit during the aura phase, and a cardiovascular safety signal. Triptans are also traditionally cautioned in this subtype. The apparent L1 support for the broader "headache disorder" prediction mostly reflects eletriptan's existing approved use in migraine, not new evidence for brainstem aura.
To proceed, the following is needed:
- Subtype-specific clinical or observational data on triptan use and safety in migraine with brainstem aura
- A review of the Singapore package insert (warnings, contraindications and approved indication), which is a blocking gap
- A cardiovascular and cerebrovascular risk assessment for this population
- A CYP3A4 and serotonergic drug-interaction management plan
- Detailed mechanism of action data from DrugBank
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.